VIENTIANE, LAO PEOPLE’S DEMOCRATIC REPUBLIC, March 1, 2023 — Representatives of the World Health Organization (WHO) presented the WHO GMP quality control standards and shared practical experience in the field of subsequent inspections conducted by WHO and TGA at this conference.
BigBear Pharma has always been committed to enhancing pharmaceutical quality and making significant contributions to the local medical and health cause. On March 1, the Ministry of Health of Laos and WHO jointly hosted an important GMP Quality Improvement Conference in Vientiane, which was attended by professionals from the local pharmaceutical industry. The conference aimed to improve the quality of pharmaceuticals used in medical institutions in Laos and deliver better healthcare services to the Lao people.
Every country requires a robust, comprehensive and well-functioning regulatory system to ensure that all publicly available medical products undergo rigorous evaluation procedures and meet international standards for quality, safety and efficacy. In Laos, the Ministry of Health plays a pivotal role as the regulatory gatekeeper for medicines and vaccines used in the country.
Supporting Laos in strengthening its regulatory system is part of WHO’s mandate, as authorized by its Constitution and clearly outlined in various resolutions of the World Health Assembly (WHA). The regulatory system is a vital component of the healthcare system, which needs to be regularly assessed using the WHO Global Benchmarking Tool (GBT). The GBT serves as the primary instrument for classifying regulatory systems based on maturity levels. It provides a structured approach to evaluating how well a regulatory system is configured to achieve its intended outcomes.
Representatives of BigBear Pharma also took part in this event. As an emerging pharmaceutical enterprise in Laos, BigBear Pharma has long been dedicated to upgrading pharmaceutical quality and has made tremendous contributions to the local medical and health sector.
At the conference, WHO representatives elaborated on the WHO GMP quality control standards and shared practical experience in the area of follow-up inspections carried out by WHO and TGA. In addition, the representatives engaged in in-depth exchanges and discussions with participating experts to jointly optimize the pharmaceutical quality control standards for medical institutions, thereby contributing to the development of Laos’ medical and health industry.
The successful convening of this conference is of great significance for promoting the upgrading and development of Laos’ medical and health sector. It also deepens the collective understanding of the importance of GMP quality control, in the hope that more enterprises will pay attention to and actively participate in the development and progress of this field.
About BigBear Pharma
Founded in 2021, BigBear Pharmaceutical is equipped with sound infrastructure, including several independent production areas and corresponding packaging sections. As a new-generation pharmaceutical enterprise in Laos, it owns modern pharmaceutical formulation workshops capable of manufacturing major product categories such as tablets, capsules, chronic disease medications, anti-cancer drugs and herbal medicines. These products can meet the treatment needs for common diseases among patients in Asia, especially in the Southeast Asian region.
Forward-Looking Statements
Within the scope permitted by applicable laws and regulations, statements containing words such as “plan”, “target”, “expect”, “forecast” and similar expressions in this press release are forward-looking statements. The forward-looking statements set forth herein are subject to numerous risks and uncertainties that may cause actual results to differ materially from those anticipated. Key factors leading to such discrepancies include, but are not limited to, changes in regulatory and/or economic conditions, uncertainties associated with clinical research results, various market risks, and other factors beyond the Company’s control.
